Comparing immunoadsorption and plasma exchange for treating Guillain-Barré Syndrome
Immunoadsorption Versus Plasma Exchange for Treatment of Guillain-Barré Syndrome (GBS)
University of Ulm · NCT04871035
This study is testing whether immunoadsorption works better than plasma exchange for treating adults with Guillain-Barré Syndrome.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Ulm (other) |
| Locations | 1 site (Ulm, Baden-Wurttemberg) |
| Trial ID | NCT04871035 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates the safety and efficacy of immunoadsorption compared to plasma exchange in patients diagnosed with Guillain-Barré Syndrome (GBS). The study aims to gather data on the outcomes of both treatment methods to determine which may be more effective for patients. Participants will be monitored for their clinical response and any adverse effects associated with the treatments. The study will include adults aged 18 and older who meet specific diagnostic criteria for GBS.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older diagnosed with Guillain-Barré Syndrome.
Not a fit: Patients with systemic infections or contraindications to immunoadsorption or plasma exchange may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could identify a more effective treatment option for patients with Guillain-Barré Syndrome.
How similar studies have performed: While there have been studies on plasma exchange for GBS, the comparative evaluation with immunoadsorption is less common, making this approach somewhat novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of Guillain-Barré Syndrome according to the diagnostic criteria proposed by Doorn et al. (Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome, Lancet neurology 2008) * age 18 years or above Exclusion Criteria: * Clinical or laboratory (C-reactive protein 20 mg/l or above, or evidence of nitrite-positive urinary tract infection) evidence of manifest systemic infection * Intake of angiotensin converting enzyme inhibitor within1 weeks before first treatment * Other contraindications against immunoadsorption or plasma exchange
Where this trial is running
Ulm, Baden-Wurttemberg
- Department of Neurology, University of Ulm — Ulm, Baden-Wurttemberg, Germany (RECRUITING)
Study contacts
- Principal investigator: Johannes Dorst, Prof — University of Ulm
- Study coordinator: Johannes Dorst, Prof
- Email: johannes.dorst@uni-ulm.de
- Phone: +49 731 177 5285
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: GBS